This multi-modal action could complement SGLT2 modulation by addressing the complex pathophysiology of diabetes beyond direct glucose reabsorption inhibition, for example, by reducing systemic inflammation or improving insulin sensitivity. The gene discussed is SLC5A2; the disease is diabetes mellitus.